Carboplatin and Paclitaxel Chemoradiation for Localized Anal Cancer in Patients Not Eligible for Mitomycin and 5-Fluorouracil
This study demonstrates promising tolerability and efficacy for weekly C/P chemoradiation for patients with anal cancer unable to receive mitomycin and 5-fluorouracil. This regimen merits further investigation in prospective clinical trials.
Authors
- Evie H. Carchman (ORCID: https://orcid.org/0000-0002-5536-7761)
- Noelle K. LoConte (ORCID: https://orcid.org/0000-0002-3883-4153)
- Charles P. Heise (ORCID: https://orcid.org/0000-0001-7610-6264)
- Jeremy D. Kratz (ORCID: https://orcid.org/0000-0003-1979-3955)
- Alyssa K. DeZeeuw
- Elise H. Lawson
- Dustin A. Deming (ORCID: https://orcid.org/0000-0003-2394-9836)
- M. Bassetti (ORCID: https://orcid.org/0000-0001-5012-8596)
- Sam Joseph Lubner (ORCID: https://orcid.org/0000-0002-5732-2938)
- Dana M. Hayden (ORCID: https://orcid.org/0000-0002-0358-529X)
- Cristina B. Sanger (ORCID: https://orcid.org/0009-0002-5875-924X)
- R. J. King
Institutions
- University of Wisconsin–Madison (US)
- University of Wisconsin Carbone Cancer Center (US)
- William S. Middleton Memorial Veterans Hospital (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-03
- DOI
- https://doi.org/10.3390/cancers16173062
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00